Scoring systems to predict thrombotic complications in solid tumor patients.
Swati Sharma1, Sumit Sahni2, Silvio Antoniak1
1UNC Blood Research Center, Department of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Current Opinion in Hematology
|February 10, 2025
Summary
Predicting cancer-associated venous thromboembolism (CAT) risk is challenging due to patient heterogeneity. This review evaluates current models and suggests improvements for better risk stratification and management.
Area of Science:
- Oncology
- Hematology
- Biostatistics
Background:
- Cancer patients face a significantly higher risk of venous thromboembolism (VTE), impacting survival and quality of life.
- Existing risk assessment methods are insufficient for the procoagulant changes in cancer, complicating individualized VTE risk prediction.
- Clinical guidelines recommend VTE risk assessment and thromboprophylaxis for cancer patients undergoing chemotherapy.
Purpose of the Study:
- To evaluate current predictive models for cancer-associated venous thromboembolism (CAT).
- To explore the use of large datasets for stratifying cancer patients into distinct VTE risk groups.
- To identify potential improvements for enhanced clinical decision-making in CAT management.
Main Methods:
- Review and analysis of existing literature on CAT risk prediction models.
- Evaluation of the strengths, limitations, and diagnostic performance of current models.
- Identification of novel variables for enhancing predictive model accuracy.
Main Results:
- Cancer-associated venous thromboembolism (CAT) poses a significant clinical challenge due to heterogeneous patient risk.
- Various predictive models exist to stratify patients, but their accuracy and utility vary.
- Current models often fail to fully capture the complexities of cancer-related VTE risk.
Conclusions:
- Existing CAT risk prediction models require further refinement.
- Incorporating additional variables can improve model effectiveness for risk stratification.
- Enhanced models will better guide clinicians in managing VTE risk in cancer patients.
